Health & Fitness
Health and Fitness
Health and Fitness
Fri, March 1, 2013Thu, February 28, 2013Wed, February 27, 2013Tue, February 26, 2013Mon, February 25, 2013Sun, February 24, 2013Sat, February 23, 2013Fri, February 22, 2013Thu, February 21, 2013Wed, February 20, 2013Tue, February 19, 2013Mon, February 18, 2013Sun, February 17, 2013Fri, February 15, 2013Thu, February 14, 2013Wed, February 13, 2013Tue, February 12, 2013Mon, February 11, 2013Sun, February 10, 2013Fri, February 8, 2013Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2012 Financial Results and Corporate Update on March 7, 2013
Published in Health and Fitness on Wednesday, February 20th 2013 at 5:46 GMT by Market Wire
February 20, 2013 08:30 ET
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2012 Financial Results and Corporate Update on March 7, 2013
CAMBRIDGE, MA--(Marketwire - Feb 20, 2013) - Sarepta Therapeutics, Inc. (
The conference call may be accessed by dialing 800.446.2782 for domestic callers and 847.413.3235 for international callers. The passcode for the call is 34143150. Please specify to the operator that you would like to join the "Sarepta Fourth Quarter and Full-Year 2012 Earnings Call." The conference call will be webcast live under the events section of Sarepta's website at [ www.sareptatherapeutics.com ] and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at [ www.sareptatherapeutics.com ].
